CommercialCoverageLow impact
08.02.37, Eladocagene exuparvovec-tneq (Kebilidi™)
Independence Blue Cross·Oncology, Hematology, Pediatrics·Pharmacy
Effective date
Nov 13, 2024
We identified it
Jun 19, 2026
Summary
A new policy has been established for Eladocagene exuparvovec-tneq (Kebilidi™), a gene therapy medication. This appears to be the first coverage policy for this new drug, which will likely include coverage criteria and prior authorization requirements for commercial plans.
Action Required
By November 13, 2024: Review the complete policy document at the provided URL to understand coverage criteria, prior authorization requirements, and billing procedures for Kebilidi™. Update billing staff on any special handling requirements for this gene therapy medication.